Seely Lynn — SEC insider filings

SEC reporting owner CIK 1327111. 23 insider filings on record with FilingPulse; latest filed 2026-11-12.

Transaction summary — filings shown

Covers all 23 filings on record, filed 2021-06-04 to 2026-11-12. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Lyell Immunopharma, Inc. (LYEL)President and CEO, Director161 leg · 175,000 sh · $106,19010 legs · 27,271 sh · $446,59212
Blueprint Medicines Corp (BPMC)Director6——21
AbCellera Biologics Inc. (ABCL)Director1——1

Insider filings — Seely Lynn

FiledFormIssuerReported transactionsSource
2026-11-124Lyell Immunopharma, Inc. (LYEL)Sale (S): 545 @ $15.93EDGAR
2026-08-254Lyell Immunopharma, Inc. (LYEL)Sale (S): 9,589 @ $15.54EDGAR
2026-08-114Lyell Immunopharma, Inc. (LYEL)Sale (S): 390 @ $14.34EDGAR
2026-07-064AbCellera Biologics Inc. (ABCL)Grant/award (A): 152,207 (derivative) @ $0EDGAR
2026-06-154Lyell Immunopharma, Inc. (LYEL)Sale (S): 388 @ $18.91EDGAR
2026-02-124Lyell Immunopharma, Inc. (LYEL)Sale (S): 7,455 @ $23.39EDGAR
2026-02-114Lyell Immunopharma, Inc. (LYEL)Grant/award (A): 20,000 @ $0 · Sale (S): 438 @ $23.12 · Grant/award (A): 155,000 (derivative) @ $0EDGAR
2025-11-124Lyell Immunopharma, Inc. (LYEL)Sale (S): 412 @ $16.11EDGAR
2025-10-294Lyell Immunopharma, Inc. (LYEL)Grant/award (A): 175,000 (derivative) @ $0EDGAR
2025-08-224Lyell Immunopharma, Inc. (LYEL)Grant/award (A): 40,000 @ $0 · Sale (S): 7,257 @ $10.54EDGAR
2025-08-134Lyell Immunopharma, Inc. (LYEL)Sale (S): 391 @ $10.53 · Sale (S): 406 @ $10.34EDGAR
2025-07-214Blueprint Medicines Corp (BPMC)Disposition to issuer (D): 3,902 · Code (U): 13,254 · Disposition to issuer (D): 21,818 (derivative) · Disposition to issuer (D): 10,909 (derivative) · Disposition to issuer (D): 10,909 (derivative) · Disposition to issuer (D): 7,500 (derivative) · +6 moreEDGAR
2025-06-244Blueprint Medicines Corp (BPMC)Grant/award (A): 3,902 @ $128.12EDGAR
2025-03-184Lyell Immunopharma, Inc. (LYEL)Purchase (P): 175,000 @ $0.61EDGAR
2025-02-264Lyell Immunopharma, Inc. (LYEL)Grant/award (A): 337,500 @ $0 · Grant/award (A): 1,350,000 (derivative) @ $0 · Grant/award (A): 168,750 (derivative) @ $0EDGAR
2024-06-144Blueprint Medicines Corp (BPMC)Grant/award (A): 2,242 @ $0 · Grant/award (A): 4,570 (derivative) @ $0EDGAR
2024-02-134Lyell Immunopharma, Inc. (LYEL)Grant/award (A): 200,000 @ $0EDGAR
2023-11-204Lyell Immunopharma, Inc. (LYEL)Grant/award (A): 7,500,000 (derivative) · Disposition to issuer (D): 7,500,000 (derivative)EDGAR
2023-06-234Blueprint Medicines Corp (BPMC)Grant/award (A): 2,600 @ $0 · Grant/award (A): 5,300 (derivative) @ $0EDGAR
2022-12-194Lyell Immunopharma, Inc. (LYEL)Grant/award (A): 7,500,000 (derivative) @ $0EDGAR
2022-06-304Blueprint Medicines Corp (BPMC)Grant/award (A): 2,600 @ $0 · Grant/award (A): 5,300 (derivative) @ $0EDGAR
2022-06-104Lyell Immunopharma, Inc. (LYEL)Grant/award (A): 65,000 (derivative) @ $0EDGAR
2021-06-044Blueprint Medicines Corp (BPMC)Grant/award (A): 2,250 @ $0 · Grant/award (A): 4,500 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-11-20 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1327111 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs